COVID-19 Helpful Information for your practice

 

For the most current up-to-date information on COVD-19 please visit:  https://www.cdc.gov/

Interim Infection Prevention and Control Recommendations for Patients with Suspected or Confirmed Coronavirus Disease 2019 (COVID-19) in Healthcare Settings

https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-recommendations.html

__________________________________________________________________________________

MERCK ACCESS and PATIENT ASSISTANCE

During this unprecedented time, Merck is committed to ensuring our medicines and vaccines reach our patients and

customers. This includes supporting patients who might need more help today with their medications, including those

who are unemployed or have lost insurance coverage due to the COVID-19 pandemic. To learn about what support

options may be available, visit our Access and Patient Assistance information page.

For more details about Merck’s response to coronavirus, visit our COVID-19 information page.

__________________________________________________________________________________

 

Takeda Oncology Here2Assist Patient DocuSign Service

Takeda Oncology understands that COVID-19 is creating unprecedented challenges for oncology practices and patients. This may include a patient’s ability to come to the clinic to sign Takeda Oncology Here2Assist enrollment forms for support services such as financial assistance. Takeda Oncology is committed to patient safety and would like to remind you that patient signatures can be obtained electronically through DocuSign.

 

If you are submitting a Takeda Oncology Here2Assist Enrollment form, RapidStart Request form or a Patient Assistance Program application without a patient signature, a Takeda Oncology Here2Assist case manager will reach out to your patient to obtain their signature via DocuSign. (Patients who do not wish to utilize DocuSign or do not have internet access will be contacted via mail for signature).

 

Please visit www.Here2Assist.com for more information about coverage support, financial assistance and educational support services that your patients may qualify for.

 

Takeda Oncology’s top priority remains ensuring continuity of care for your patients and ensuring they receive medicines required for treatment. Like you, we are committed to doing what we can to help protect patients, healthcare professionals and the stakeholders we serve.

 

As your Takeda Oncology Regional Account Executive, I will remain proactively engaged and available to you, providing information you may need. Due to the current environment, please note that I will communicate with your organization primarily via phone, email, and digital or video conferencing at this time.

 

You may always reach me by mobile phone at (443) 605-5696 or via email at scott.friedly@takeda.com. You may also contact the Takeda Oncology Here2Assist patient support service line at 844-817-6468 for product related questions.

__________________________________________________________________________________

CMS Recommendations on Elective Surgeries

If necessary, please consult with your organization’s health care expert to determine what is best for the patients you serve, especially with respect to infusions or other HOPD non-surgery procedures. Importantly, CMS emphasizes that decisions about care remain in the hands of state and local health officials and physicians with direct responsibility to their patients.

Information from Janssen Pharmaceuticals

The COVID-19 pandemic has changed life for all of us, disrupting family and work routines seemingly in a matter of days. For patients who already face health challenges, COVID-19 can make it even more difficult to access care for their conditions. It is critical that patients have continuity of care as the COVID-19 crisis evolves, and as a partner to POHMS, we want to support you in ensuring that patients will continue to receive the medications they were, and will be, prescribed.

You may have seen the recent guidance from CMS to limit non-essential surgeries and procedures – see attached. If necessary, please consult with your organization’s health care expert to determine what is best for the patients you serve, especially with respect to infusions or other HOPD non-surgery procedures. Importantly, CMS emphasizes that decisions about care remain in the hands of state and local health officials and physicians with direct responsibility to their patients.

In these extraordinary times, we remain firm in our belief that treatment decisions belong with patients and their health care providers. Ensuring stability and continuity of care remains critical and switching of a clinically stable patient from their current therapy should be based on an informed decision by patients with their physicians.

We understand your priority right now is meeting the needs of your patients and practice. At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are here to help. Below are important updates: 

  • Patient Programs: Janssen CarePath will continue to provide patient support resources through our call center and provider portal. Call volumes may increase, which may result in longer-than-normal wait times. Janssen has a variety of other patient and provider programs that support fulfillment and use of our medicines. We are striving to continue to meet the needs of our customers with these programs. Please visit  https://www.janssencarepath.com for more information including contact numbers. 
  • Medical Information: The Janssen Medical Information Center is staffed to meet your needs virtually. For medical information inquiries, contact us by visiting http://askjanssenmedinfo.com/ or by calling 1-800-Janssen (1-800-526-7736). 

Know also that as this crisis unfolds, Johnson & Johnson is taking steps to help prevent the spread of the coronavirus (COVID-19), exploring the potential for a vaccine, and acting on robust business continuity plans to meet the needs of those who depend on our products.  

 

For more information on Johnson & Johnson’s response to COVID-19, please visit our website at www.jnj.com/latest-news.